Literature DB >> 32602114

PharmVar GeneFocus: CYP2C19.

Mariana R Botton1, Michelle Whirl-Carrillo2, Andria L Del Tredici3, Katrin Sangkuhl2, Larisa H Cavallari4, José A G Agúndez5, Jorge Duconge6, Ming Ta Michael Lee7, Erica L Woodahl8, Karla Claudio-Campos4, Ann K Daly9, Teri E Klein2, Victoria M Pratt10, Stuart A Scott11,12, Andrea Gaedigk13.   

Abstract

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation impacts the metabolism of many drugs and has been associated with both efficacy and safety issues for several commonly prescribed medications. This GeneFocus provides a comprehensive overview and summary of CYP2C19 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
© 2020 The Author. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32602114      PMCID： PMC7769975          DOI： 10.1002/cpt.1973

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  77 in total

1.  Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.

Authors:  M Romkes; M B Faletto; J A Blaisdell; J L Raucy; J A Goldstein
Journal:  Biochemistry       Date:  1991-04-02       Impact factor: 3.162

2.  In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population.

Authors:  Da-Peng Dai; Li-Ming Hu; Pei-Wu Geng; Shuang-Hu Wang; Jie Cai; Guo-Xin Hu; Jian-Ping Cai
Journal:  Xenobiotica       Date:  2015-07-07       Impact factor: 1.908

3.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

4.  Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles.

Authors:  M Ingelman-Sundberg; M Oscarson; A K Daly; S Garte; D W Nebert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-12       Impact factor: 4.254

5.  Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation.

Authors:  M Takahashi; T Saito; M Ito; C Tsukada; Y Katono; H Hosono; M Maekawa; M Shimada; N Mano; A Oda; N Hirasawa; M Hiratsuka
Journal:  Pharmacogenomics J       Date:  2014-07-08       Impact factor: 3.550

Review 6.  Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology.

Authors:  Victoria M Pratt; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Stuart A Scott; Karen E Weck
Journal:  J Mol Diagn       Date:  2018-02-21       Impact factor: 5.568

7.  In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.

Authors:  Souzan B Yanni; Pieter P Annaert; Patrick Augustijns; Joseph G Ibrahim; Daniel K Benjamin; Dhiren R Thakker
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

8.  Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes.

Authors:  Ibrahim Numanagić; Salem Malikić; Michael Ford; Xiang Qin; Lorraine Toji; Milan Radovich; Todd C Skaar; Victoria M Pratt; Bonnie Berger; Steve Scherer; S Cenk Sahinalp
Journal:  Nat Commun       Date:  2018-02-26       Impact factor: 14.919

9.  The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro.

Authors:  Ren-Ai Xu; Er-Min Gu; Teng-Hui Liu; Qiu-Geng Ou-Yang; Guo-Xin Hu; Jian-Ping Cai
Journal:  Infect Drug Resist       Date:  2018-11-01       Impact factor: 4.003

10.  Long-Distance Phasing of a Tentative "Enhancer" Single-Nucleotide Polymorphism With CYP2D6 Star Allele Definitions.

Authors:  Erin C Boone; Wendy Y Wang; Roger Gaedigk; Mariana Cherner; Anick Bérard; J Steven Leeder; Neil A Miller; Andrea Gaedigk
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810
View more
  17 in total

1.  The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups.

Authors:  Khalifa Y Alrajeh; Youssef M Roman
Journal:  Per Med       Date:  2022-06-24       Impact factor: 2.119

2.  Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review.

Authors:  Rahel Tekeste; Gregorio Garza; Song Han; Jianli Dong
Journal:  AIMS Mol Sci       Date:  2022-04-28

Review 3.  PharmVar GeneFocus: CYP3A5.

Authors:  Cristina Rodriguez-Antona; Jessica L Savieo; Volker M Lauschke; Katrin Sangkuhl; Britt I Drögemöller; Danxin Wang; Ron H N van Schaik; Andrei A Gilep; Arul P Peter; Erin C Boone; Bronwyn E Ramey; Teri E Klein; Michelle Whirl-Carrillo; Victoria M Pratt; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2022-02-24       Impact factor: 6.903

4.  CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.

Authors:  Andrea Gaedigk; Erin C Boone; Steven E Scherer; Seung-Been Lee; Ibrahim Numanagić; Cenk Sahinalp; Joshua D Smith; Sean McGee; Aparna Radhakrishnan; Xiang Qin; Wendy Y Wang; Emily G Farrow; Nina Gonzaludo; Aaron L Halpern; Deborah A Nickerson; Neil A Miller; Victoria M Pratt; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2022-02-05       Impact factor: 5.341

Review 5.  PharmVar GeneFocus: CYP2C9.

Authors:  Katrin Sangkuhl; Karla Claudio-Campos; Larisa H Cavallari; Jose A G Agundez; Michelle Whirl-Carrillo; Jorge Duconge; Andria L Del Tredici; Mia Wadelius; Mariana Rodrigues Botton; Erica L Woodahl; Stuart A Scott; Teri E Klein; Victoria M Pratt; Ann K Daly; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-07-12       Impact factor: 6.903

6.  Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation.

Authors:  Andrea Gaedigk; Scott T Casey; Michelle Whirl-Carrillo; Neil A Miller; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2021-06-29       Impact factor: 6.903

Review 7.  PharmVar GeneFocus: CYP2B6.

Authors:  Zeruesenay Desta; Ahmed El-Boraie; Li Gong; Andrew A Somogyi; Volker M Lauschke; Collet Dandara; Kathrin Klein; Neil A Miller; Teri E Klein; Rachel F Tyndale; Michelle Whirl-Carrillo; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-03-11       Impact factor: 6.903

8.  Utility of the 13 C-pantoprazole breath test as a CYP2C19 phenotyping probe for children.

Authors:  Keith Feldman; Gregory L Kearns; Robin E Pearce; Susan M Abdel-Rahman; James Steven Leeder; Alec Friesen; Vincent S Staggs; Andrea Gaedigk; Jaylene Weigel; Valentina Shakhnovich
Journal:  Clin Transl Sci       Date:  2022-02-14       Impact factor: 4.438

Review 9.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

Review 10.  Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.

Authors:  Thomas Helland; Sarah Alsomairy; Chenchia Lin; Håvard Søiland; Gunnar Mellgren; Daniel Louis Hertz
Journal:  J Pers Med       Date:  2021-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.